Skip to main content
BioPorto logo

BioPorto — Investor Relations & Filings

Ticker · BIOPOR ISIN · DK0011048619 LEI · 5299004SWFL5JAN4W830 CO Manufacturing
Open in API
Filings indexed 788 across all filing types
Latest filing 2020-04-30 Share Issue/Capital Cha…
Country DK Denmark
Listing CO BIOPOR

About BioPorto

https://bioporto.com/

BioPorto is an in vitro diagnostics company specializing in actionable biomarkers to improve kidney health. The company's primary focus is the development and commercialization of diagnostic tests based on the Neutrophil Gelatinase-Associated Lipocalin (NGAL) biomarker for the early risk assessment and diagnosis of acute kidney injury (AKI). Its product portfolio includes The NGAL Test™ for clinical use and the FDA-cleared ProNephro AKI (NGAL) test for pediatric applications. These tools enable clinicians to detect kidney damage earlier than traditional methods, facilitating timely intervention. BioPorto also provides a range of NGAL ELISA kits and antibodies for preclinical and clinical research settings.

Recent filings

Filing Released Lang Actions
Share capital and votes
Share Issue/Capital Change Classification · 95% confidence The document is a short announcement from BioPorto regarding a change in share capital and total voting rights, issued pursuant to the Danish Capital Markets Act. It does not report a specific transaction in own shares (buyback) or a new share issuance event, but rather provides a formal update on the current capital structure. Given it is a regulatory disclosure regarding share capital status, it fits best under the 'Share Issue/Capital Change' category as it pertains to the total share capital and voting rights.
2020-04-30 English
Share capital and votes
Share Issue/Capital Change Classification · 95% confidence The document is a short announcement (1,212 characters) regarding the total number of shares and voting rights in BioPorto, issued pursuant to the Danish Capital Markets Act. It does not represent a full financial report or a major shareholding notification, but rather a regulatory disclosure of capital structure. Given it is a standard regulatory announcement regarding share capital, it fits best under the RNS category.
2020-04-30 English
BioPorto A/S has initiated a rights issue with pre-emptive rights for its existing shareholders
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement from BioPorto A/S regarding the initiation of a rights issue (a capital increase) for existing shareholders. It details the subscription price, the number of new shares, the subscription period, and the strategic reasons for the offering. This falls under the category of share issuance and capital changes.
2020-03-16 English
Capital/Financing Update 2020
Capital/Financing Update Classification · 98% confidence The document explicitly announces the initiation of a 'rights issue' (an offering of new shares with pre-emptive rights to existing shareholders) by BioPorto A/S. This action involves increasing the company's share capital and setting a subscription price. This directly relates to fundraising, financing activities, and changes to the capital structure. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a simple Dividend Notice (DIV). The document details the terms of the capital raise, not just an announcement of a report.
2020-03-16 English
Progress Update on BioPorto’s Activities to Strengthen its Financial Position
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a rights issue (a capital raising activity) by BioPorto. It details the revision of the subscription price and the progress of commitments for new shares. This falls under the category of capital/financing updates as it describes the company's efforts to strengthen its financial position through a share offering.
2020-03-16 English
Share Issue/Capital Change 2020
Share Issue/Capital Change Classification · 99% confidence The document is titled "Progress Update on BioPorto’s Activities to Strengthen its Financial Position" and details revisions to a planned rights issue, including subscription price changes and committed proceeds (DKK 28 million out of a potential DKK 39.9 million). This clearly relates to fundraising and capital structure changes. The filing is an official announcement (Announcement no. 5) dated March 16, 2020. This content directly matches the definition for Capital/Financing Update (CAP). Although it mentions that additional information is expected later, the core content is the financing update itself, not just an announcement of a future report, thus ruling out RPA/RNS as the primary classification.
2020-03-16 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.